Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-la

Abstract

This study examines the course of patient-reported side effect during the first 4 months of treatment for multiple sclerosis (MS) with interferon beta-Ia (IFNβ-Ia), and the relationship of those side effects to discontinuation of medication. Flu-like symptoms, muscle aches and chills decreased over the first 2 months of treatment but did not change over the second 2 months. Loss of feeling or numbness, tingling and depression increased over 4 months, however these side effects were generally mild. Loss of feeling or numbness and tingling at 2 month follow-up were significantly related to discontinuation of IFNβ-Ia by 4 month follow-up.

Keywords

interferon multiple sclerosis side effects compliance

Get full access to this article

View all access options for this article.

References

Jacobs LD et al. (1996) Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis . Ann Neurol 39: 285-294 .

Kurtzke JR (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurol 33: 1444-1452 .

Mohr DC et al. (1996) Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment . Multiple Schlerosis 2: 222-226 .

Neilley LK , Goodin DS , Goodkin DE , Hauser SL (1996) Side effect profile of interferon beta-lb in MS: Results of an open label trial . Neurol 46: 552-554 .

Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis . Ann Neurol 13: 227-231 .

Sharrack B , Hughes RAC , Soudain S. (1996) Guy's Neurological Disability Scale . Journal of Neurology 243: P171-P171 .